Multiple endocrine neoplasia syndromes

Molecular Pathology in Clinical Practice

Volumn , Issue , 2007, Pages 233-242

  Zehnbauer, Barbara ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70350510394     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-33227-7_20     Document Type: Chapter

References (51)

1. Phay JE, Moley JF, Lairmore TC. Multiple endocrine neoplasias. Semin Surg Oncol. 2000;18:324-332
2. Eng C. Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med. 1996;335:943-951
3. Wautot V, Vercherat C, Lespinasse J, et al. Germline mutation profile of MEN1 in multiple endocrine neoplasias type 1: Search for correlations between phenotype and the functional domains of the MEN1 protein. Hum Mutat. 2002;20:35-47
4. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-Type 1. Science. 1997;276:404-407
5. Gagel RF, Marx SJ. In: Larsen PR, Kronenberg H, Melmed S, Polonsky K. eds. Multiple Endocrine Neoplasias.Williams Textbook of Endocrinology. 10th ed. Orlando, FL: WB Saunders; 2002:1717-1762
6. Agarwal SK, Guru SC, Heppner C, et al.Menin interacts with the AP1 transcription factor JunD and represses JunD-Activated transcription. Cell. 1999;96:143-152
7. Bertolino P, Radovanovic I, Casse H, et al. Genetic ablation of the tumor suppressor menin causes lethality at mid-gestation with defects in multiple organs. Mech Dev. 2003;120:549-560
8. Crabtre JS, Scacheri PC, Ward JM, et al. Of mice and MEN1: Insulinomas in a conditional mouse knockout. Mol Cell Biol. 2003;23: 6075-6085
9. Libutti SK, Crabtree JS, Lorang D, et al. Parathyroid gland-specific deletion of the mouse Men1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism. Cancer Res. 2003;63:8022-8028
10. Guo SS, Sawicki MP.Molecular and genetic mechanisms of tumorigenesis in multiple endocrine neoplasia type 1. Mol Endocrinol. 2001;15:1653-1664
11. Marx SJ.Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer. 2005;5:367-375
12. Mutch MG, Dilley WG, Sanjurjo F, et al. Germline mutations in the multiple endocrine neoplasias type 1 gene: Evidence for frequent splicing defects. Hum Mutat. 1999;13:175-185
13. Agarwal SK, Kester MB, Debelenko LV, et al. Germline mutations in the MEN1 gene in familial multiple endocrine neoplasias type 1 and related states. Hum Mol Genet. 1997;6:1169-1175
14. Gite S, Lim M, Carlson R, et al. A high-Throughput non-isotopic protein truncation test. Nat Biotech. 2003;21:194-197
15. Traverso G, Shuber A, Levin B, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med. 2002;346:311-320
16. Kishi M, Tsukada T, Shimizu S, et al. A large germline deletion of the MEN1 gene in a family with multiple endocrine neoplasia type 1. Jpn J Cancer Res. 1998;89:1-5
17. Lairmore TC, Piersall LD, DeBenedetti MK, et al. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasias type1 (MEN1). Ann Surg. 2004;239:637-647
18. Crabtree JS, Scacheri PC, Ward JM, et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci U S A. 2001;98:1118-1123
19. Cupisti K, Hoppner W, Dotzenrath C, et al. Lack of MEN1 gene mutations in 27 sporadic insulinomas. Eur J Clin Invest. 2000;30:325-329
20. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasias type 2A. Nature. 1993;363:458-460
21. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET protooncogene are associated with MEN2A and FMTC. Hum Mol Genet. 1993;2:851-856
22. Pichel JG, Shen L, Sheng HZ, et al. Defects in enteric innervation and kidney development in mice lacking GDNF. Nature. 1996;382:73-76
23. Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasias type 2B and sporadic medullary thyroid carcinoma. Nature. 1994;367:375-376
24. Carlson KM, Dou S, Chi D, et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET proto-oncogene associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A. 1994;91:1579-1583
25. Santoro M, Carlomagno F, Romano A, et al. Activation of RET as a dominantly transforming gene by germline mutations of MEN2A and MEN2B. Science. 1995;267:381-383
26. Bolino A, Schuffernecker I, Luo Y, et al. RET mutations in exons 13 and 14 of FMTC patients. Oncogene. 1995;10:2415-2419
27. Eng C, Smith DP, Mulligan LM, et al. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma. Oncogene. 1995;10:509-513
28. Edery P, Lyonnet S, Mulligan LM, et al.Mutations of the RET protooncogene in Hirschsprung's disease. Nature. 1994;367:378-380
29. Romeo G, Ronchetto P, Luo Y, et al. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature. 1994;367:377-378
30. Borst MJ, VanCamp JM, Peacock ML, Decker RA. Mutational analysis of multiple endocrine neoplasias type 2A associated with Hirschsprung's disease. Surgery. 1995;117:386-391
31. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the RET proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990; 60:557-563
32. Musholt PB, Musholt TJ, Goodfellow PJ, et al. Cold single-stranded conformational variants for mutation analysis of the RET protooncogene. Surgery. 1997;122:363-370
33. Peacock ML, Borst MJ, Sweet JD, Decker RA. Detection of RET mutations in multiple endocrine neoplasias type 2A and familial medullary thyroid carcinoma by denaturing gradient gel electrophoresis. Hum Mutat. 1996;7:100-104
34. Ceccherini I, Hofstra RMW, Luo Y. DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the RET proto-oncogene. Oncogene. 1994;9:3025-3029
35. Siegelman M, Mohabeer A, Fahey TJ III, et al. Rapid, nonradioactive screening for mutations in exons 10, 11, and 16 of the RET protooncogene associated with inherited medullary thyroid carcinoma. Clin Chem. 1997;43:453-457
36. Liu W, Smith DI, Rechtzigel KJ, et al. Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations. Nucleic Acids Res. 1998;26:1396-1400
37. Wells SA Jr, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg. 1994;220:237-250
38. Chen X, Zehnbauer B, Gnirke A, et al. Fluorescence energy transfer detection as a homogeneous DNA diagnostic method. Proc Natl Acad Sci U S A. 1997;94:10756-10761
39. Howe JR, Lairmore TC, Mishra SK, et al. Improved predictive test for MEN2, using flanking dinucleotide repeats and RFLPs. Am J Hum Genet. 1992;51:1430-1442
40. Noll WW. Utility of RET mutation analysis in multiple endocrine neoplasia type 2. Arch Pathol Lab Med. 1999;123:1047-1049
41. Baloh RH, Tansey MG, Lampe PA, et al. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRa3-RET receptor complex. Neuron. 1998;21:1291-1302
42. Zedenius J, Larsson C, Bergholm U, et al.Mutations of codon 918 in the RET proto-oncogene correlate with poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab. 1995;80: 3088-3090
43. Eng C, Mulligan LM. Mutations of the RET proto-oncogene in the multiple endocrine neoplasias type 2 syndromes, related sporadic tumors, and Hirschsprung disease. Hum Mutat. 1997;9:97-109
44. Neumann HPH, Eng C, Mulligan LM, et al. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia type II. JAMA. 1995;274:1149-1151
45. Ledger GA, Khosla S, Lindor NM, et al. Genetic testing in the diagnosis and management of multiple endocrine neoplasia type II. Ann Intern Med. 1995;122:118-124
46. Gagel RF, Core GJ, Bugalho MJMG, et al. Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A. J Intern Med. 1995;238:331-341
47. Lips CJM, Landsvater RM, Hoppener JWM, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med. 1994;331:828-835
48. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002;62:7284-7290
49. Moley JF. Medullary thyroid carcinoma. Curr Treat Options Oncol. 2003;4:339-347
50. Kruckeberg KE, Thibodeau SN. Pyrosequencing technology as a method for the diagnosis of multiple endocrine neoplasia type 2. Clin Chem. 2004;50:522-529
51. Ahmed SA, Snow-Bailey K, Highsmith WE, et al.Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases. J Mol Diagn. 2005;7:283-288